Arrowhead Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Arrowhead Pharmaceuticals is Chris Anzalone, benoemd in Dec2007, heeft een ambtstermijn van 15.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.03M, bestaande uit 7.2% salaris en 92.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.84% van de aandelen van het bedrijf, ter waarde MX$ 935.82M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 12.9 jaar.

Belangrijke informatie

Chris Anzalone

Algemeen directeur

US$12.0m

Totale compensatie

Percentage CEO-salaris	7.2%
Dienstverband CEO	15.8yrs
Eigendom CEO	1.8%
Management gemiddelde ambtstermijn	6.4yrs
Gemiddelde ambtstermijn bestuur	12.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Anzalone's beloning veranderd ten opzichte van Arrowhead Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m
Jun 30 2018	n/a	n/a	-US$54m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	n/a	n/a	-US$35m
Sep 30 2017	US$2m	US$616k	-US$34m

Compensatie versus markt: De totale vergoeding ($USD 12.03M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 1.29M ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Anzalone (54 yo)

15.8yrs

Tenure

US$12,031,969

Compensatie

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Anzalone	CEO, President & Director	15.8yrs	US$12.03m	1.84% MX$ 935.8m
Kenneth Myszkowski	Chief Financial Officer	13.7yrs	US$4.74m	0.21% MX$ 107.0m
Patrick O'Brien	COO, General Counsel & Secretary	8.8yrs	US$4.73m	0.39% MX$ 196.2m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$4.32m	0.18% MX$ 89.5m
Tracie Oliver	Chief Commercial Officer	1.3yrs	US$2.97m	0.066% MX$ 33.5m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	geen gegevens	geen gegevens
Vincent Anzalone	Head of Investor Relations & VP	no data	geen gegevens	geen gegevens
Howard Lovy	Director of Communications	18.2yrs	geen gegevens	geen gegevens
Mark Seefeld	Head of Toxicology & VP	no data	geen gegevens	geen gegevens
Javier San Martin	Chief Medical Officer	3.9yrs	US$658.48k	0.050% MX$ 25.6m
Aaron Tan	Head of Tax	1.8yrs	geen gegevens	geen gegevens
Nadia Meshkova	VP & Treasurer	1.8yrs	geen gegevens	geen gegevens

6.4yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARWR * is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Anzalone	CEO, President & Director	15.8yrs	US$12.03m	1.84% MX$ 935.8m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	geen gegevens	geen gegevens
Douglass Given	Chairman of the Board	12.9yrs	US$472.28k	0.13% MX$ 64.2m
Michael Perry	Independent Lead Director	11.8yrs	US$457.28k	0.086% MX$ 43.6m
William Waddill	Independent Director	5.8yrs	US$467.28k	0.027% MX$ 13.7m
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	geen gegevens	geen gegevens
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	geen gegevens	geen gegevens
Mauro Ferrari	Independent Director	13.2yrs	US$457.28k	0.040% MX$ 20.4m
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	geen gegevens	geen gegevens
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	geen gegevens	geen gegevens
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	geen gegevens	geen gegevens
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	geen gegevens	geen gegevens

12.9yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARWR * zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.9 jaar).

Arrowhead Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Insufficient new directors

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Recent updates

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Insufficient new directors

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Full year 2022 earnings released: US$1.67 loss per share (vs US$1.36 loss in FY 2021)

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd